Exact Sciences, along with the Mayo Clinic, reports that early research using blood-based methylated DNA markers demonstrate a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer, the company announced today.

“These pancreatic cancer data showcase the strength of our market discovery collaboration with Mayo Clinic, a partnership that is fueling our product pipeline,” Exact Sciences CEO Kevin Conroy said in a statement. “We aim to identify a minimally invasive marker for a disease that often goes undetected until it progresses to an advanced stage, when fewer treatment options exist.”

According to a release, the results came from a 340-sample, case-control study.

The findings were presented at Digestive Disease Week 2019, which takes place May 18-21 at the San Diego Convention Center.